Why Is VIKING THERAPEUTICS (VKTX) Stock Down Today?

Why VKTX stock is down today

Viking Therapeutics shares fell 14.41% to $35.65 on Thursday, marking one of the stock's worst days in over a year. The steep decline followed the company's announcement of a $500 million upsized public offering of common stock and convertible senior notes. The offering, which priced 7.86 million shares at $35 each and included $225 million in 2% convertible senior notes, was priced at a 16% discount to the stock’s closing price the prior day. The move significantly diluted existing shareholders and raised concerns about the company’s capital needs and valuation.

What Happened

The offering, announced late Wednesday, included a concurrent secondary offering and convertible note issuance. Viking priced the common shares at $35 per share, below the $41.65 close on Wednesday, creating a 9.6% gap down at the open. The stock continued to decline throughout the session, reaching a low of $35.11 before closing at $35.69. The offering is intended to fund the development of Viking’s obesity drug candidates, VK2735 and VK3019. However, the steep discount and large size of the offering raised red flags among investors, who interpreted the move as a sign of financial pressure and a lack of confidence in the stock’s intrinsic value.

What The Data Shows

The stock opened at $37.65 and traded down for the entire session, with volume reaching 10.1 million shares, or 4.6 times the 3-month average. The stock had previously gained 32.1% over the last 8 sessions, rising from $31.53 to $41.65. However, the recent insider selling by top executives, including the CEO, CFO, and COO, added to the negative sentiment. The company has no recent insider buying and has seen three sales totaling $6.3 million in the last 90 days. Additionally, unusual options activity showed a $2.8 million call premium with no put activity, suggesting some short-term speculative positioning.

What To Watch

Viking Therapeutics has no scheduled earnings in the near term. Investors will likely monitor the breadth of coverage and sentiment shifts in the coming days, particularly as the market digests the implications of the large financing and its impact on shareholder value.